News | August 15, 2024
Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
India Business grew by 11.9% YoY to Rs. 1196.2 crore
India Business grew by 11.9% YoY to Rs. 1196.2 crore
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
This project is supported by the Irish Government through IDA Ireland
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Our centers are performing as expected or even better
Subscribe To Our Newsletter & Stay Updated
